Ivana Vranić

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

William J. Sandborn, Subrata Ghosh, Julián Panés et al. · New England Journal of Medicine · 2012 · 799 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Christina Charles‐Schoeman, Maya H Buch, Maxime Dougados et al. · Annals of the Rheumatic Diseases · 2022 · 204 citations · Full text

Medicine, Cardiology, Pharmacology +17

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

Jeffrey R. Curtis, Kunihiro Yamaoka, Yi‐Hsing Chen et al. · Annals of the Rheumatic Diseases · 2022 · 160 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial

Robert Bissonnette, Ana B. Pavel, Aisleen Diaz et al. · Journal of Allergy and Clinical Immunology · 2019 · 124 citations · Full text

Medicine, Dermatology, Pharmacology +14

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

William J. Sandborn, Geert D’Haens, Bruce E. Sands et al. · Journal of Crohn s and Colitis · 2022 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15